PR93773

LUND, Sweden, Dec. 17, 2021 /PRNewswire=KYODO JBN/--

Syntach AB in Lund, Sweden has been awarded Euro 2.5 million as a grant and

part of blended finance of up to Euro 17,5 million from the European Innovation

Council (EIC) to support the development of its unique minimally invasive

cardiac support system.

Over 60 million people suffer from heart failure, and it is one of the most

common causes of death globally. A cardiac support system can prolong and save

many lives. Syntach AB is developing a minimally invasive left ventricular

assist system that, unlike current systems, does not require open heart surgery

to be implanted. Further, it is powered by an implanted battery, avoiding a

drive line through the skin and many of the negative side effects associated

with conventional left ventricular assist devices.

Rather than replacing the heart function, the Syntach system supports and

enhances the natural movement of the mitral valve plane in the heart, making

each heartbeat more effective. Minimizing blood exposure to foreign material

allows a biocompatible and physiological interaction that further reduces

negative side effects.

The EIC has been set up within the EU Horizon Europe program. The aim is to

identify and support pioneering new technology and innovation from early

research to market launch and scaling up internationally. The funding awarded

by the EIC will allow Syntach to accelerate the development of its implantable,

minimally invasive cardiac support system.

"We are proud and happy to have been awarded this recognition and support of a

potentially game-changing new treatment that may help hundreds of thousands of

patients, adding years of quality life," says Prof. Jan Solem, Syntach AB's CEO

and inventor.

Tor Peters, Chairman of the Board says: "It is our objective to revolutionize

the way heart failure patients are treated while creating a company with the

capability to offer this treatment on a global scale. A lot of work remains,

but we have a fantastic team in place and paired with the great support from

patients, as well as the global interventional cardiology and cardiac surgery

communities, we are very optimistic about our future."

Syntach AB is based in Lund, Sweden and develops innovative cardiac support

systems as well as mitral valve intervention systems in cooperation with

several academic research centres. Syntach works with the Cardiac MR Group at

the Department for Clinical Sciences and Clinical Physiology at Lund

University. The academic team at Lund University has pioneered the research

about the functioning of the heart.

Logo - https://mma.prnewswire.com/media/1712747/Syntach_Logo.jpg

Source:  Syntach AB